Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Has Average Price Target of $1.71 According to Brokerages

Posted by Brian Himes on Oct 17th, 2026

Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) has earned a consensus rating of “Reduce” from the six analysts that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $1.71.

Several research firms have weighed in on PACB. UBS Group initiated coverage on Pacific Biosciences of California in a report on Wednesday, September 9th. They issued a “neutral” rating and a $1.35 price objective for the company. Weiss Ratings raised Pacific Biosciences of California from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. Finally, Wall Street Zen cut Pacific Biosciences of California from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th.

Check Out Our Latest Research Report on PACB

Pacific Biosciences of California Trading Down 11.7%

Shares of PACB stock traded down $0.23 during mid-day trading on Friday, reaching $1.73. The stock had a trading volume of 10,417,223 shares, compared to its average volume of 20,225,270. The firm has a market capitalization of $537.74 million, a PE ratio of -4.02 and a beta of 2.19. The stock’s 50-day moving average price is $1.61 and its two-hundred day moving average price is $1.50. Pacific Biosciences of California has a 52-week low of $1.07 and a 52-week high of $3.44.

Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) last posted its earnings results on Monday, August 3rd. The biotechnology company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). The firm had revenue of $39.01 million for the quarter, compared to analysts’ expectations of $42.90 million. Pacific Biosciences of California had a negative return on equity of 5,752.12% and a negative net margin of 82.49%. On average, equities research analysts forecast that Pacific Biosciences of California will post -0.52 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider James Gibson, II sold 661,815 shares of Pacific Biosciences of California stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $3.11, for a total value of $2,058,244.65. Following the sale, the insider owned 1,083,848 shares in the company, valued at $3,370,767.28. The trade was a 37.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark Van Oene sold 26,911 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1.13, for a total transaction of $30,409.43. Following the transaction, the insider directly owned 2,705,853 shares in the company, valued at approximately $3,057,613.89. The trade was a 0.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 3.70% of the company’s stock.

Hedge Funds Weigh In On Pacific Biosciences of California

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Essential Partners LLC purchased a new stake in Pacific Biosciences of California in the first quarter worth about $25,000. Corient Private Wealth LP bought a new stake in Pacific Biosciences of California during the 2nd quarter valued at approximately $30,000. Pinegrove Venture Partners LLC bought a new stake in Pacific Biosciences of California during the 2nd quarter valued at approximately $34,584. Legal & General Group Plc purchased a new position in shares of Pacific Biosciences of California during the 2nd quarter worth approximately $46,000. Finally, Clear Harbor Asset Management LLC purchased a new position in shares of Pacific Biosciences of California during the 2nd quarter worth approximately $50,000.

Pacific Biosciences of California Company Profile

(Get Free Report)

Pacific Biosciences of California, Inc develops and sells advanced genetic sequencing technologies. The company’s platform is based on single-molecule, real-time (SMRT) sequencing, which is designed to produce highly accurate, long DNA reads. These reads can help researchers identify genetic variation, assemble genomes, and analyze complex biological systems that may be difficult to study using short-read sequencing methods.

PacBio’s product portfolio includes the Revio and Sequel IIe sequencing systems, SMRT Cells and other consumables, library-preparation products, and software for instrument operation, data analysis, and interpretation.